Register      Login
Microbiology Australia Microbiology Australia Society
Microbiology Australia, bringing Microbiologists together

Articles citing this paper

A brief survey of interventional agents intended to treat Long COVID

Ross T. Barnard A * and Evan B. Siegel B
+ Author Affiliations
- Author Affiliations

A School of Chemistry and Molecular Biosciences, The University of Queensland, Saint Lucia, Qld 4072, Australia.

B Ground Zero Pharmaceuticals, Inc., 5325 Alton Parkway Suite C-464, Irvine, CA 92604, USA.




Emeritus Professor Ross Barnard is a former Director of the Biotechnology Program at the University of Queensland and a Fellow of the ASM. He was a Principal investigator in the ARC Training Centre for Biopharmaceutical Innovation. He is a member of the editorial board of Microbiology Australia.



Evan B. Siegel, PhD is CEO of Ground Zero Pharmaceuticals, Inc., which provides regulatory affairs and related consulting services to pharmaceutical and biotechnology firms worldwide. Dr Siegel served in senior positions in pharma and biotechnology. He was a toxicologist at the US FDA and California Department of Health. Dr Siegel is an Adjunct Professor at the University of Queensland, Brisbane, an Adjunct Professor at the Queensland University of Technology, and a visiting professor at the University of California—Irvine, USA.

* Correspondence to: rossbarnard@uq.edu.au

Microbiology Australia 45(1) 22-26 https://doi.org/10.1071/MA24008
Submitted: 30 December 2023  Accepted: 16 February 2024   Published: 6 March 2024



1 articles found in Crossref database.

Contextualising COVID-19 in 2024
Walker Gregory, Rawlinson William
Microbiology Australia. 2024 45(1). p.3

Committee on Publication Ethics

Abstract Full Text PDF (1.4 MB) Export Citation

Share

Share on Facebook Share on Twitter Share on LinkedIn Share via Email